Top Qs
Timeline
Chat
Perspective
Maralixibat chloride
Chemical compound From Wikipedia, the free encyclopedia
Remove ads
Maralixibat chloride, sold under the brand name Livmarli, is a medication used to treat cholestatic pruritus in people with Alagille syndrome.[5][6] Maralixibat chloride is an ileal bile acid transporter (IBAT) inhibitor.[5]
The most common side effects include diarrhea and abdominal pain (belly ache).[6]
Maralixibat chloride was approved for medical use in the United States in September 2021,[5][7][8][9] and in the European Union in December 2022.[6]
Remove ads
Medical uses
Maralixibat chloride is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome.[5][6]
History
The U.S. Food and Drug Administration (FDA) granted the application for maralixibat chloride orphan drug designations in 2013,[10][11] and in 2020.[12][13]
Society and culture
Legal status
In October 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Livmarli, intended for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS).[14] The applicant for this medicinal product is Mirum Pharmaceuticals International B.V.[14] Maralixibat chloride was approved for medical use in the European Union in December 2022.[6][15]
Names
Maralixibat chloride is the international nonproprietary name (INN).[16]
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads